Medicxi turns six into one, with launch of new immuno-dermatology firm
12 Feb 2024
Immunotherapy
Medicxi is pooling assets from six of its companies to form a new drugmaker focused on more than a dozen immuno-dermatology programmes for indications such as atopic dermatitis, vitiligo, alopecia areata and chronic spontaneous urticaria. The firm, called Alys Pharmaceuticals, has also bagged $100 million in financing from Medicxi.
Francesco De Rubertis, a partner at Medicxi who will serve as Alys chairman, said “we believe that bringing together several asset-centric companies…will power up Alys to transform innovation in immuno-dermatology.” De Rubertis noted that Alys’ pipeline, which is based on multiple platform technologies and includes programmes focused on underserved indications such as mastocytosis, cutaneous T-cell lymphoma, carries “diverse risk profiles and will hugely benefit from this change of scale and facilitated access to capital."
Alys combines Aldena Therapeutics, Graegis Pharmaceuticals, Granular Therapeutics, Klirna Biotech, Nira Biosciences and Vimela Therapeutics. The drugmaker indicated that over the next three years, it hopes to deliver between seven to 10 clinical proof-of-concept readouts, and potentially at least one programme to advance to registrational studies.
The company will be run by co-founder and chief operating officer Thibaud Portal, who formerly served as Galderma's global head of prescription medicines.
More to come.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.